for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bavarian Nordic A/S

BAVA.CO

Latest Trade

190.00DKK

Change

0.00(0.00%)

Volume

148,730

Today's Range

186.70

 - 

190.85

52 Week Range

117.75

 - 

195.60

As of on the Copenhagen Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
190.00
Open
190.85
Volume
148,730
3M AVG Volume
2.66
Today's High
190.85
Today's Low
186.70
52 Week High
195.60
52 Week Low
117.75
Shares Out (MIL)
32.36
Market Cap (MIL)
6,153.92
Forward P/E
-18.98
Dividend (Yield %)
--

Latest Developments

More

Bavarian Nordic Q2 EBIT Loss Narrows To DKK 97.0 Million

Bavarian Nordic Says Share Buy-Back Program Announced And Initiated On May 22, 2019, Terminated

Bavarian Nordic Jan-March EBIT Loss Narrows To DKK 104 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bavarian Nordic A/S

Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The Company is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.

Industry

Biotechnology & Drugs

Contact Info

Hejreskovvej 10A

+45.33.268383

http://www.bavarian-nordic.com

Executive Leadership

Gerard W. M. van Odijk

Independent Chairman of the Board

Paul John Chaplin

President, Chief Executive Officer

Anders Gersel Pedersen

Independent Deputy Chairman of the Board

Henrik Juuel

Executive Vice President, Chief Financial Officer

Henrik Birk

Executive Vice President, Chief Operating Officer

Key Stats

2.00 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, DKK)

2016

1.0K

2017

1.4K

2018

0.5K

2019(E)

0.6K
EPS (DKK)

2016

1.000

2017

5.700

2018

-11.200

2019(E)

-10.012
Price To Earnings (TTM)
--
Price To Sales (TTM)
9.75
Price To Book (MRQ)
3.09
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
23.40
LT Debt To Equity (MRQ)
22.58
Return on Investment (TTM)
-10.68
Return on Equity (TTM)
-9.31

Latest News

BRIEF-Bavarian Nordic REPORTS Positive Result From Phase 2 Trial Evaluating BN-Brachyury In Chordoma

* REPORTED ON WEDNESDAY POSITIVE RESULT FROM ONGOING PHASE 2 TRIAL EVALUATING BN-BRACHYURY IN CHORDOMA

BRIEF-Bavarian Nordic FY EBIT Rises To DKK 353.2 Million

* FY EBIT DKK 353.2 MILLION VERSUS DKK 33.0 MILLION YEAR AGO

BRIEF-Bavarian Nordic Announces Phase 2 Trial Investigating Combination Of Its Immunotherapy CV301 And Nivolumab In Microsatellite Stable Colorectal Cancer

* BAVARIAN NORDIC ANNOUNCES PHASE 2 TRIAL INVESTIGATING COMBINATION OF ITS IMMUNOTHERAPY CV301 AND NIVOLUMAB IN MICROSATELLITE STABLE COLORECTAL CANCER

BRIEF-Bavarian Nordic: Additional Positive Data From Phase 2 Study

* REG-BAVARIAN NORDIC ANNOUNCES ADDITIONAL POSITIVE DATA FROM A PHASE 2 STUDY OF ITS UNIVERSAL RSV VACCINE

BRIEF-Bavarian Nordic: Collaboration to Evaluate CV301 in Combination with durvalumab

* REG-BAVARIAN NORDIC ANNOUNCES COLLABORATION TO EVALUATE CV301 IN COMBINATION WITH DURVALUMAB IN COLORECTAL AND PANCREATIC CANCERS

BRIEF-Bavarian Nordic Announces Positive Results Of Pivotal Phase 3 Study Of Imvamune Smallpox Vaccine

* BAVARIAN NORDIC ANNOUNCES POSITIVE RESULTS OF PIVOTAL PHASE 3 STUDY OF IMVAMUNE® SMALLPOX VACCINE

BRIEF-Bavarian Nordic Announces Planned Departure Of CFO Ole Larsen

* BAVARIAN NORDIC ANNOUNCES THE PLANNED DEPARTURE OF CHIEF FINANCIAL OFFICER, OLE LARSEN

BRIEF-Bavarian Nordic Initiates Clinical Trial With Novel Cancer Immunotherapy

* REG-BAVARIAN NORDIC ANNOUNCES INITIATION OF CLINICAL TRIAL WITH NOVEL CANCER IMMUNOTHERAPY TARGETING BRACHYURY IN CANCER METASTASIS

Merkel's allies, further defying SPD, seek cuts to tax and asylum seeker benefits

Germany's Bavarian conservatives are pressing for corporate tax cuts and cuts to welfare payments for asylum seekers, which could complicate talks with the Social Democrats (SPD) on forming a new government.

BRIEF-Bavarian Nordic Q3 EBIT at DKK 432 million

* Q3 EBIT DKK 432.0 MILLION VERSUS LOSS DKK 124.8 MILLION YEAR AGO

SGS and Bavarian Nordic developing challenge strain to combat respiratory virus​

SGS and Bavarian Nordic are teaming up to develop a virus challenge strain to combat a common respiratory illness.

Bavarian Nordic eyes more U.S. government contracts after new vaccine order

Danish drug maker Bavarian Nordic <BAVA.CO> expects to win further U.S. contracts for its smallpox vaccine after it secured a key government order, the company said on Thursday.

BRIEF-Bavarian Nordic wins big smallpox vaccine order for U.S. government

* SECURES CONTRACT AWARD FOR SUPPLY OF FREEZE-DRIED IMVAMUNE SMALLPOX VACCINE TO THE U.S. GOVERNMENT

BRIEF-Bavarian Nordic provides update on its RSV vaccine

* REG-BAVARIAN NORDIC PROVIDES UPDATE ON ITS UNIVERSAL RSV VACCINE

BRIEF-Bavarian Nordic says independent Data Monitoring Committee determined continuation of Phase 3 prospect study of Prostvac is futile

* Independent Data Monitoring Committee recommends discontinuation of Bavarian Nordic's Phase 3 study of Prostvac in metastatic prostate cancer

Bavarian Nordic says first milestone payment under J&J deal could be in 2019

Danish biotech company Bavarian Nordic expects to get its first milestone payment under a deal with Janssen Pharmaceuticals in 2019, if clinical trials for vaccines targeting hepatitis B and HIV-1 get underway next year, a company executive said.

Bavarian Nordic says first milestone payment under new J&J deal could be in 2019

Danish biotech company Bavarian Nordic expects to get a first milestone payment under a new deal with Janssen Pharmaceuticals in 2019, if clinical trials for vaccines targeting hepatitis B and HIV-1 get underway next year, a company executive said.

BRIEF-Bavarian Q2 EBIT at DKK 102.3 million

* Q2 REVENUE DKK 397.3 MILLION VERSUS DKK 116.6 MILLION YEAR AGO

UPDATE 1-Bavarian expands J&J deal to HIV and hepatitis B vaccines, shares jump

Danish biotech company Bavarian Nordic has expanded its collaboration with Janssen Pharmaceuticals, a unit of Johnson & Johnson, to also grant the U.S. drugmaker the exclusive rights to its MVA-BN technology for vaccine programmes targeting hepatitis B and HIV-1.

BRIEF-Bavarian Nordic in deal with Janssen for development of vaccine regimens

* REG-BAVARIAN NORDIC ANNOUNCES AGREEMENT WITH JANSSEN FOR THE DEVELOPMENT OF VACCINE REGIMENS AGAINST HIV-1 AND HEPATITIS B

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up